Pseudomonas aeruginosa: Host defence in lung diseases

Respirology

Volumn 15, Issue 7, 2010, Pages 1037-1056

  Williams, Bryan J ^a   Dehnbostel, Joanne ^a   Blackwell, Timothy S ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

biofilm; innate immunity; mucosal immunity; Pseudomonas aeruginosa; respiratory infection

Indexed keywords

BACTERIAL TOXIN; BETA DEFENSIN; COLLECTIN; COMPLEMENT COMPONENT C1Q; CYTOSOL RECEPTOR; CYTOTOXIN; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MANNOSE BINDING LECTIN 2; MUCIN; MYELOID DIFFERENTIATION FACTOR 88; N (3 OXODODECANOYL)HOMOSERINE LACTONE; PATTERN RECOGNITION RECEPTOR; PYOCYANINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VIRULENCE FACTOR;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; APOPTOSIS; BACTERIAL FLAGELLUM; BACTERIAL SURVIVAL; BACTERIUM PILUS; BIOFILM; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS; BRONCHITIS; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; CYSTIC FIBROSIS; DENDRITIC CELL; EOSINOPHIL; EPITHELIUM CELL; FLAGELLUM; HOSPITAL INFECTION; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; INNATE IMMUNITY; LUNG INFECTION; LYMPHOCYTE; MACROPHAGE; MUCOCILIARY CLEARANCE; MUCOSAL IMMUNITY; NEUTROPENIA; NEUTROPHIL; NONHUMAN; NUTRIENT; PATHOGENICITY; PERMEABILITY BARRIER; PERSISTENT INFECTION; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT MUCOSA; REVIEW; VIRULENCE;

ANIMALS; BIOFILMS; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS; CROSS INFECTION; CYSTIC FIBROSIS; CYTOKINES; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LEUKOCYTES; LUNG DISEASES; MICE; MUCUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, PATTERN RECOGNITION; VIRULENCE FACTORS;

EID: 77957267856     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01819.x     Document Type: Review

References (233)

1. Campa M, Bendinelli M, Friedman H. Pseudomonas Aeruginosa as an Opportunistic Pathogen. Springer
2. Rahme LG, Stevens EJ, Wolfort SF et al. Common virulence factors for bacterial pathogenicity in plants and animals. Science 1995 268 : 1899 902.
3. Burns JL, Gibson RL, McNamara S et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J. Infect. Dis. 2001 183 : 444 52. (Pubitemid 32105604)
4. Safdar N, Crnich CJ, Maki DG. The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for prevention. Respir. Care 2005 50 : 725 39. (Pubitemid 46187578)
5. Bragonzi A, Paroni M, Nonis A et al. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am. J. Respir. Crit. Care Med. 2009 180 : 138 45.
6. Smith EE, Buckley DG, Wu Z et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl. Acad. Sci. U.S.A. 2006 103 : 8487 92. (Pubitemid 43838482)
7. Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. Eur. J. Clin. Microbiol. Infect. Dis. 1996 15 : 281 5.
8. Koulenti D, Lisboa T, Brun-Buisson C et al. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit. Care Med. 2009 37 : 2360 8.
9. Anand N, Kollef MH. The alphabet soup of pneumonia: CAP, HAP, HCAP, NHAP, and VAP. Semin. Respir. Crit. Care Med. 2009 30 : 3 9.
10. Craven DE, Chroneou A, Zias N et al. Ventilator-associated tracheobronchitis: the impact of targeted antibiotic therapy on patient outcomes. Chest 2009 135 : 521 8.
11. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2005 171 : 388 416. (Pubitemid 40227463)
12. Richards MJ, Edwards JR, Culver DH et al. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect. Control Hosp. Epidemiol. 2000 21 : 510 15.
13. Crouch BS, Wunderink RG, Jones CB et al. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996 109 : 1019 29.
14. Parkins MD, Gregson DB, Pitout JD et al. Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection 2010 38 : 25 32.
15. Lodise TP Jr., Patel N, Kwa A et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob. Agents Chemother. 2007 51 : 3510 15. (Pubitemid 47519337)
16. Hauser AR, Cobb E, Bodi M et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit. Care Med. 2002 30 : 521 8. (Pubitemid 34214611)
17. Harris AD, Smith D, Johnson JA et al. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin. Infect. Dis. 2002 34 : 340 5. (Pubitemid 34062234)
18. Trautmann M, Lepper PM, Haller M. Ecology of Pseudomonas aeruginosa in the intensive care unit and the evolving role of water outlets as a reservoir of the organism. Am. J. Infect. Control 2005 33 : S41 9. (Pubitemid 44302021)
19. Heyland DK, Cook DJ, Griffith L et al. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am. J. Respir. Crit. Care Med. 1999 159 : 1249 56. (Pubitemid 29202563)
20. Pugin J, Dunn-Siegrist I, Dufour J et al. Cyclic stretch of human lung cells induces an acidification and promotes bacterial growth. Am. J. Respir. Cell Mol. Biol. 2008 38 : 362 70. (Pubitemid 351567706)
21. Adair CG, Gorman SP, Feron BM et al. Implications of endotracheal tube biofilm for ventilator-associated pneumonia. Intensive Care Med. 1999 25 : 1072 6.
22. Beer D, Vandermeer B, Brosnikoff C et al. Bacterial contamination of health care workers' pagers and the efficacy of various disinfecting agents. Pediatr. Infect. Dis. J. 2006 25 : 1074 5. (Pubitemid 44657821)
23. Girou E, Schortgen F, Delclaux C et al. Association of noninvasive ventilation with nosocomial infections and survival in critically ill patients. JAMA 2000 284 : 2361 7.
24. Weber DJ, Rutala WA, Sickbert-Bennett EE et al. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect. Control Hosp. Epidemiol. 2007 28 : 825 31.
25. Kollef MH, Shorr A, Tabak YP et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005 128 : 3854 62. (Pubitemid 43062645)
26. Scannapieco FA, Stewart EM, Mylotte JM. Colonization of dental plaque by respiratory pathogens in medical intensive care patients. Crit. Care Med. 1992 20 : 740 5.
27. McEachern R, Campbell GD Jr. Hospital-acquired pneumonia: epidemiology, etiology, and treatment. Infect. Dis. Clin. North Am. 1998 12 : 761 79, x.
28. Chatzinikolaou I, Abi-Said D, Bodey GP et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch. Intern. Med. 2000 160 : 501 9. (Pubitemid 30112273)
29. Whitecar JP Jr., Luna M, Bodey GP. Pseudomonas bacteremia in patients with malignant diseases. Am. J. Med. Sci. 1970 60 : 216 23.
30. Bodey GP. Pseudomonas aeruginosa infections in cancer patients: have they gone away? Curr. Opin. Infect. Dis. 2001 14 : 403 7.
31. Carratala J, Roson B, Fernandez-Sevilla A et al. Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch. Intern. Med. 1998 158 : 868 72. (Pubitemid 28183641)
32. Rhee CK, Kang JY, Kim YH et al. Risk factors for acute respiratory distress syndrome during neutropenia recovery in patients with hematologic malignancies. Crit. Care 2009 13 : R173.
33. Hirschtick RE, Glassroth J, Jordan MC et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N. Engl. J. Med. 1995 333 : 845 51.
34. Vidal F, Mensa J, Martinez JA et al. Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1. Eur. J. Clin. Microbiol. Infect. Dis. 1999 18 : 473 7. (Pubitemid 29531186)
35. Afessa B, Green B. Bacterial pneumonia in hospitalized patients with HIV infection: the Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study. Chest 2000 117 : 1017 22. (Pubitemid 30228357)
36. Domingo P, Ferre A, Baraldes MA et al. Pseudomonas aeruginosa bronchopulmonary infection in patients with AIDS, with emphasis on relapsing infection. Eur. Respir. J. 1998 12 : 107 12. (Pubitemid 28183654)
37. Domingo P, Ferre A, Baraldes MA et al. Remission of relapsing Pseudomonas aeruginosa bronchopulmonary infection following antiretroviral therapy. Arch. Intern. Med. 1998 158 : 929 30. (Pubitemid 28183654)
38. Almirall J, Bolibar I, Vidal J et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur. Respir. J. 2000 15 : 757 63. (Pubitemid 30196306)
39. Liam CK, Lim KH, Wong CM. Community-acquired pneumonia in patients requiring hospitalization. Respirology 2001 6 : 259 64.
40. Sopena N, Sabria M, Pedro-Botet ML et al. Prospective study of community-acquired pneumonia of bacterial etiology in adults. Eur. J. Clin. Microbiol. Infect. Dis. 1999 18 : 852 8. (Pubitemid 30066162)
41. El-Solh AA, Sikka P, Ramadan F et al. Etiology of severe pneumonia in the very elderly. Am. J. Respir. Crit. Care Med. 2001 163 : 645 51. (Pubitemid 32230823)
42. Arancibia F, Bauer TT, Ewig S et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch. Intern. Med. 2002 162 : 1849 58.
43. Hatchette TF, Gupta R, Marrie TJ. Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature. Clin. Infect. Dis. 2000 31 : 1349 56.
44. Torres A, Menendez R. Mortality in COPD patients with community-acquired pneumonia: who is the third partner? Eur. Respir. J. 2006 28 : 262 3. (Pubitemid 44914222)
45. Restrepo MI, Mortensen EM, Pugh JA et al. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur. Respir. J. 2006 28 : 346 51.
46. Anzueto A, Niederman MS, Tillotson GS. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group. Clin. Ther. 1998 20 : 885 900. (Pubitemid 28535725)
47. Patel IS, Seemungal TA, Wilks M et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002 57 : 759 64. (Pubitemid 34984972)
48. Papi A, Bellettato CM, Braccioni F et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006 173 : 1114 21. (Pubitemid 43726892)
49. Lode H, Allewelt M, Balk S et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007 35 : 143 9. (Pubitemid 46932325)
50. Murphy TF, Brauer AL, Eschberger K et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008 177 : 853 60. (Pubitemid 351600663)
51. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009 373 : 1891 904.
52. Stutts MJ, Canessa CM, Olsen JC et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995 269 : 847 50.
53. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N. Engl. J. Med. 2005 352 : 1992 2001. (Pubitemid 40638370)
54. Jacques I, Derelle J, Weber M et al. Pulmonary evolution of cystic fibrosis patients colonized by Pseudomonas aeruginosa and/or Burkholderia cepacia. Eur. J. Pediatr. 1998 157 : 427 31. (Pubitemid 28225449)
55. Ashlock MA, Beall RJ, Hamblett NM et al. A pipeline of therapies for cystic fibrosis. Semin. Respir. Crit. Care Med. 2009 30 : 611 26.
56. Davies JC, Bilton D. Bugs, biofilms, and resistance in cystic fibrosis. Respir. Care 2009 54 : 628 40.
57. Hassett DJ, Sutton MD, Schurr MJ et al. Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways. Trends Microbiol. 2009 17 : 130 8.
58. Smith AL, Fiel SB, Mayer-Hamblett N et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003 123 : 1495 502. (Pubitemid 36549768)
59. Etherington C, Hall M, Conway S et al. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis. J. Antimicrob. Chemother. 2008 61 : 425 7.
60. Branda SS, Vik S, Friedman L et al. Biofilms: the matrix revisited. Trends Microbiol. 2005 13 : 20 6. (Pubitemid 40082393)
61. Bilton D. Update on non-cystic fibrosis bronchiectasis. Curr. Opin. Pulm. Med. 2008 14 : 595 9.
62. Tsang KW, Bilton D. Clinical challenges in managing bronchiectasis. Respirology 2009 14 : 637 50.
63. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir. Med. 2007 101 : 1163 70. (Pubitemid 46667677)
64. Bush A, Chodhari R, Collins N et al. Primary ciliary dyskinesia: current state of the art. Arch. Dis. Child. 2007 92 : 1136 40. (Pubitemid 350221463)
65. Gremmo ML, Guenza MC. Positive expiratory pressure in the physiotherapeutic management of primary ciliary dyskinesia in paediatric age. Monaldi Arch. Chest Dis. 1999 54 : 255 7.
66. Noone PG, Bennett WD, Regnis JA et al. Effect of aerosolized uridine-5′-triphosphate on airway clearance with cough in patients with primary ciliary dyskinesia. Am. J. Respir. Crit. Care Med. 1999 160 : 144 9.
67. Homma H, Yamanaka A, Tanimoto S et al. Diffuse panbronchiolitis. A disease of the transitional zone of the lung. Chest 1983 83 : 63 9. (Pubitemid 13172752)
68. Azuma A, Kudoh S. Diffuse panbronchiolitis in East Asia. Respirology 2006 11 : 249 61.
69. Kudoh S, Azuma A, Yamamoto M et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am. J. Respir. Crit. Care Med. 1998 157 : 1829 32. (Pubitemid 28311266)
70. Tanimoto H. A review of the recent progress in treatment of patients with diffuse panbronchiolitis associated with Pseudomonas aeruginosa infection in Japan. Antibiot. Chemother. 1991 44 : 94 8.
71. Kobayashi H, Takeda H, Sakayori S et al. [Study on azithromycin in treatment of diffuse panbronchiolitis]. Kansenshogaku Zasshi 1995 69 : 711 22.
72. Fujii T, Kadota J, Kawakami K et al. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995 50 : 1246 52.
73. Nagai H, Shishido H, Yoneda R et al. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991 58 : 145 9.
74. Lopez-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr. Opin. Pharmacol. 2008 8 : 286 91.
75. Vos R, Vanaudenaerde BM, Geudens N et al. Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation? Eur. Respir. J. 2008 31 : 1037 45.
76. Botha P, Archer L, Anderson RL et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008 85 : 771 4. (Pubitemid 351398256)
77. Nunley DR, Grgurich W, Iacono AT et al. Allograft colonization and infections with Pseudomonas in cystic fibrosis lung transplant recipients. Chest 1998 113 : 1235 43. (Pubitemid 28223810)
78. Vos R, Vanaudenaerde BM, De Vleeschauwer SI et al. De novo or persistent pseudomonal airway colonization after lung transplantation: importance for bronchiolitis obliterans syndrome? Transplantation 2008 86 : 624 5.
79. Walter S, Gudowius P, Bosshammer J et al. Epidemiology of chronic Pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis. Thorax 1997 52 : 318 21. (Pubitemid 27204891)
80. Moser C, Hougen HP, Song Z et al. Early immune response in susceptible and resistant mice strains with chronic Pseudomonas aeruginosa lung infection determines the type of T-helper cell response. APMIS 1999 107 : 1093 100. (Pubitemid 30016634)
81. Dunkley ML, Clancy RL, Cripps AW. A role for CD4+ T cells from orally immunized rats in enhanced clearance of Pseudomonas aeruginosa from the lung. Immunology 1994 83 : 362 9.
82. Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc. Natl. Acad. Sci. U.S.A. 1997 94 : 12088 93. (Pubitemid 27467847)
83. Schroeder TH, Lee MM, Yacono PW et al. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc. Natl. Acad. Sci. U.S.A. 2002 99 : 6907 12.
84. Di A, Brown ME, Deriy LV et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat. Cell Biol. 2006 8 : 933 44. (Pubitemid 44314724)
85. Stover CK, Pham XQ, Erwin AL et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000 406 : 959 64.
86. Liberati NT, Urbach JM, Miyata S et al. An ordered, nonredundant library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants. Proc. Natl. Acad. Sci. U.S.A. 2006 103 : 2833 8. (Pubitemid 43306635)
87. Mathee K, Narasimhan G, Valdes C et al. Dynamics of Pseudomonas aeruginosa genome evolution. Proc. Natl. Acad. Sci. U.S.A. 2008 105 : 3100 5. (Pubitemid 351723674)
88. Lau GW, Hassett DJ, Britigan BE. Modulation of lung epithelial functions by Pseudomonas aeruginosa. Trends Microbiol. 2005 13 : 389 97.
89. Deziel E, Comeau Y, Villemur R. Initiation of biofilm formation by Pseudomonas aeruginosa 57RP correlates with emergence of hyperpiliated and highly adherent phenotypic variants deficient in swimming, swarming, and twitching motilities. J. Bacteriol. 2001 183 : 1195 204. (Pubitemid 32107715)
90. Moreau-Marquis S, Stanton BA, O'Toole GA. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm. Pharmacol. Ther. 2008 21 : 595 9. (Pubitemid 351970710)
91. Bjarnsholt T, Jensen PO, Fiandaca MJ et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr. Pulmonol. 2009 44 : 547 58.
92. Whitchurch CB, Tolker-Nielsen T, Ragas PC et al. Extracellular DNA required for bacterial biofilm formation. Science 2002 295 : 1487. (Pubitemid 34173996)
93. Pedersen SS, Kharazmi A, Espersen F et al. Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect. Immun. 1990 58 : 3363 8. (Pubitemid 20293447)
94. Wozniak DJ, Wyckoff TJ, Starkey M et al. Alginate is not a significant component of the extracellular polysaccharide matrix of PA14 and PAO1 Pseudomonas aeruginosa biofilms. Proc. Natl. Acad. Sci. U.S.A. 2003 100 : 7907 12. (Pubitemid 36760068)
95. Cobb LM, Mychaleckyj JC, Wozniak DJ et al. Pseudomonas aeruginosa flagellin and alginate elicit very distinct gene expression patterns in airway epithelial cells: implications for cystic fibrosis disease. J. Immunol. 2004 173 : 5659 70.
96. Boles BR, Thoendel M, Singh PK. Genetic variation in biofilms and the insurance effects of diversity. Microbiology 2005 151 : 2816 18. (Pubitemid 41309555)
97. Mena A, Smith EE, Burns JL et al. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J. Bacteriol. 2008 190 : 7910 17.
98. Boles BR, Singh PK. Endogenous oxidative stress produces diversity and adaptability in biofilm communities. Proc. Natl. Acad. Sci. U.S.A. 2008 105 : 12503 8.
99. Cheng K, Smyth RL, Govan JR et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996 348 : 639 42. (Pubitemid 26293808)
100. Feldman M, Bryan R, Rajan S et al. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect. Immun. 1998 66 : 43 51. (Pubitemid 28018799)
101. Adamo R, Sokol S, Soong G et al. Pseudomonas aeruginosa flagella activate airway epithelial cells through asialoGM1 and toll-like receptor 2 as well as toll-like receptor 5. Am. J. Respir. Cell Mol. Biol. 2004 30 : 627 34. (Pubitemid 38591213)
102. Caiazza NC, Merritt JH, Brothers KM et al. Inverse regulation of biofilm formation and swarming motility by Pseudomonas aeruginosa PA14. J. Bacteriol. 2007 189 : 3603 12.
103. Kopp E, Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr. Opin. Immunol. 2003 15 : 396 401. (Pubitemid 36930075)
104. Ernst RK, Hajjar AM, Tsai JH et al. Pseudomonas aeruginosa lipid A diversity and its recognition by Toll-like receptor 4. J. Endotoxin Res. 2003 9 : 395 400.
105. Ernst RK, Moskowitz SM, Emerson JC et al. Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis. J. Infect. Dis. 2007 196 : 1088 92.
106. Cigana C, Curcuru L, Leone MR et al. Pseudomonas aeruginosa exploits lipid A and muropeptides modification as a strategy to lower innate immunity during cystic fibrosis lung infection. PLoS One 2009 4 : e8439.
107. Worlitzsch D, Tarran R, Ulrich M et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 2002 109 : 317 25. (Pubitemid 34141805)
108. Hauser AR. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat. Rev. Microbiol. 2009 7 : 654 65.
109. Kaufman MR, Jia J, Zeng L et al. Pseudomonas aeruginosa mediated apoptosis requires the ADP-ribosylating activity of exoS. Microbiology 2000 146 (Pt 10 2531 41.
110. Lee VT, Smith RS, Tummler B et al. Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection. Infect. Immun. 2005 73 : 1695 705. (Pubitemid 40470758)
111. Phillips RM, Six DA, Dennis EA et al. In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors. J. Biol. Chem. 2003 278 : 41326 32.
112. Sato H, Frank DW, Hillard CJ et al. The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU. EMBO J. 2003 22 : 2959 69. (Pubitemid 36758617)
113. Yahr TL, Vallis AJ, Hancock MK et al. ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. Proc. Natl. Acad. Sci. U.S.A. 1998 95 : 13899 904.
114. Cowell BA, Evans DJ, Fleiszig SM. Actin cytoskeleton disruption by ExoY and its effects on Pseudomonas aeruginosa invasion. FEMS Microbiol. Lett. 2005 250 : 71 6.
115. Jain M, Ramirez D, Seshadri R et al. Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. J. Clin. Microbiol. 2004 42 : 5229 37. (Pubitemid 39506234)
116. Schuster M, Greenberg EP. A network of networks: quorum-sensing gene regulation in Pseudomonas aeruginosa. Int. J. Med. Microbiol. 2006 296 : 73 81. (Pubitemid 43375989)
117. Pesci EC, Milbank JB, Pearson JP et al. Quinolone signaling in the cell-to-cell communication system of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U.S.A. 1999 96 : 11229 34.
118. Schuster M, Lostroh CP, Ogi T et al. Identification, timing, and signal specificity of Pseudomonas aeruginosa quorum-controlled genes: a transcriptome analysis. J. Bacteriol. 2003 185 : 2066 79. (Pubitemid 36363167)
119. Wagner VE, Bushnell D, Passador L et al. Microarray analysis of Pseudomonas aeruginosa quorum-sensing regulons: effects of growth phase and environment. J. Bacteriol. 2003 185 : 2080 95. (Pubitemid 36363168)
120. Davies DG, Parsek MR, Pearson JP et al. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998 280 : 295 8.
121. Sakuragi Y, Kolter R. Quorum-sensing regulation of the biofilm matrix genes (pel) of Pseudomonas aeruginosa. J. Bacteriol. 2007 189 : 5383 6. (Pubitemid 47076084)
122. Hogardt M, Roeder M, Schreff AM et al. Expression of Pseudomonas aeruginosa exoS is controlled by quorum sensing and RpoS. Microbiology 2004 150 : 843 51. (Pubitemid 38519305)
123. Dietrich LE, Price-Whelan A, Petersen A et al. The phenazine pyocyanin is a terminal signalling factor in the quorum sensing network of Pseudomonas aeruginosa. Mol. Microbiol. 2006 61 : 1308 21. (Pubitemid 44215429)
124. Karatuna O, Yagci A. Analysis of the quorum sensing-dependent virulence factor production and its relationship with antimicrobial susceptibility in Pseudomonas aeruginosa respiratory isolates. Clin. Microbiol. Infect. 2010 doi:10.1111/j.1469-691.2010.03177.x
125. Middleton B, Rodgers HC, Camara M et al. Direct detection of N-acylhomoserine lactones in cystic fibrosis sputum. FEMS Microbiol. Lett. 2002 207 : 1 7. (Pubitemid 34214797)
126. Favre-Bonte S, Chamot E, Kohler T et al. Autoinducer production and quorum-sensing dependent phenotypes of Pseudomonas aeruginosa vary according to isolation site during colonization of intubated patients. BMC Microbiol. 2007 7 : 33. (Pubitemid 46652056)
127. Nalca Y, Jansch L, Bredenbruch F et al. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob. Agents Chemother. 2006 50 : 1680 8.
128. Smith RS, Fedyk ER, Springer TA et al. IL-8 production in human lung fibroblasts and epithelial cells activated by the Pseudomonas autoinducer N-3-oxododecanoyl homoserine lactone is transcriptionally regulated by NF-kappa B and activator protein-2. J. Immunol. 2001 167 : 366 74.
129. Chun CK, Ozer EA, Welsh MJ et al. Inactivation of a Pseudomonas aeruginosa quorum-sensing signal by human airway epithelia. Proc. Natl. Acad. Sci. U.S.A. 2004 101 : 3587 90.
130. D'Argenio DA, Wu M, Hoffman LR et al. Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol. Microbiol. 2007 64 : 512 33. (Pubitemid 46632635)
131. Kessler E, Safrin M, Abrams WR et al. Inhibitors and specificity of Pseudomonas aeruginosa LasA. J. Biol. Chem. 1997 272 : 9884 9. (Pubitemid 27171656)
132. Park PW, Pier GB, Preston MJ et al. Syndecan-1 shedding is enhanced by LasA, a secreted virulence factor of Pseudomonas aeruginosa. J. Biol. Chem. 2000 275 : 3057 64.
133. Park PW, Pier GB, Hinkes MT et al. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 2001 411 : 98 102.
134. Lau GW, Hassett DJ, Ran H et al. The role of pyocyanin in Pseudomonas aeruginosa infection. Trends Mol. Med. 2004 10 : 599 606. (Pubitemid 39573151)
135. Wilson R, Pitt T, Taylor G et al. Pyocyanin and 1-hydroxyphenazine produced by Pseudomonas aeruginosa inhibit the beating of human respiratory cilia in vitro. J. Clin. Invest. 1987 79 : 221 9. (Pubitemid 17232522)
136. Denning GM, Iyer SS, Reszka KJ et al. Phenazine-1-carboxylic acid, a secondary metabolite of Pseudomonas aeruginosa, alters expression of immunomodulatory proteins by human airway epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003 285 : L584 92.
137. Plotkowski MC, Povoa HC, Zahm JM et al. Early mitochondrial dysfunction, superoxide anion production, and DNA degradation are associated with non-apoptotic death of human airway epithelial cells induced by Pseudomonas aeruginosa exotoxin A. Am. J. Respir. Cell Mol. Biol. 2002 26 : 617 26.
138. Morlon-Guyot J, Mere J, Bonhoure A et al. Processing of Pseudomonas aeruginosa exotoxin A is dispensable for cell intoxication. Infect. Immun. 2009 77 : 3090 9.
139. Jaffar-Bandjee MC, Lazdunski A, Bally M et al. Production of elastase, exotoxin A, and alkaline protease in sputa during pulmonary exacerbation of cystic fibrosis in patients chronically infected by Pseudomonas aeruginosa. J. Clin. Microbiol. 1995 33 : 924 9.
140. Barker AP, Vasil AI, Filloux A et al. A novel extracellular phospholipase C of Pseudomonas aeruginosa is required for phospholipid chemotaxis. Mol. Microbiol. 2004 53 : 1089 98. (Pubitemid 39120431)
141. Wretlind B, Pavlovskis OR. Pseudomonas aeruginosa elastase and its role in pseudomonas infections. Rev. Infect. Dis. 1983 5 (Suppl. 5 S998 1004.
142. Mariencheck WI, Alcorn JF, Palmer SM et al. Pseudomonas aeruginosa elastase degrades surfactant proteins A and D. Am. J. Respir. Cell Mol. Biol. 2003 28 : 528 37.
143. Zulianello L, Canard C, Kohler T et al. Rhamnolipids are virulence factors that promote early infiltration of primary human airway epithelia by Pseudomonas aeruginosa. Infect. Immun. 2006 74 : 3134 47. (Pubitemid 43794502)
144. Kownatzki R, Tummler B, Doring G. Rhamnolipid of Pseudomonas aeruginosa in sputum of cystic fibrosis patients. Lancet 1987 1 : 1026 7. (Pubitemid 17057866)
145. Whitsett JA. Intrinsic and innate defenses in the lung: intersection of pathways regulating lung morphogenesis, host defense, and repair. J. Clin. Invest. 2002 109 : 565 9.
146. Balkovetz DF, Katz J. Bacterial invasion by a paracellular route: divide and conquer. Microbes Infect. 2003 5 : 613 19. (Pubitemid 36645121)
147. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J. Clin. Invest. 2002 109 : 571 7.
148. Boucher RC. An overview of the pathogenesis of cystic fibrosis lung disease. Adv. Drug Deliv. Rev. 2002 54 : 1359 71.
149. Lazarowski ER, Boucher RC. Purinergic receptors in airway epithelia. Curr. Opin. Pharmacol. 2009 9 : 262 7.
150. Shah AS, Ben-Shahar Y, Moninger TO et al. Motile cilia of human airway epithelia are chemosensory. Science 2009 325 : 1131 4.
151. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010 327 : 291 5.
152. Kuroki Y, Takahashi M, Nishitani C. Pulmonary collectins in innate immunity of the lung. Cell. Microbiol. 2007 9 : 1871 9. (Pubitemid 47087079)
153. Dorfman R, Sandford A, Taylor C et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J. Clin. Invest. 2008 118 : 1040 9. (Pubitemid 351364611)
154. Zhang S, McCormack FX, Levesque RC et al. The flagellum of Pseudomonas aeruginosa is required for resistance to clearance by surfactant protein A. PLoS One 2007 2 : e564. (Pubitemid 351260402)
155. Ganz T. Defensins: antimicrobial peptides of vertebrates. C. R. Biol. 2004 327 : 539 49. (Pubitemid 38979504)
156. Kim C, Slavinskaya Z, Merrill AR et al. Human alpha-defensins neutralize toxins of the mono-ADP-ribosyltransferase family. Biochem. J. 2006 399 : 225 9. (Pubitemid 44570284)
157. Yanagi S, Ashitani J, Imai K et al. Significance of human beta-defensins in the epithelial lining fluid of patients with chronic lower respiratory tract infections. Clin. Microbiol. Infect. 2007 13 : 63 9. (Pubitemid 44869209)
158. Tesse R, Cardinale F, Santostasi T et al. Association of beta-defensin-1 gene polymorphisms with Pseudomonas aeruginosa airway colonization in cystic fibrosis. Genes Immun. 2008 9 : 57 60. (Pubitemid 351150035)
159. Goldman MJ, Anderson GM, Stolzenberg ED et al. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997 88 : 553 60.
160. Gakhar L, Bartlett JA, Penterman J et al. PLUNC is a novel airway surfactant protein with anti-biofilm activity. PLoS One 2010 5 : e9098.
161. Vandivier RW, Ogden CA, Fadok VA et al. Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J. Immunol. 2002 169 : 3978 86.
162. Schultz DR, Miller KD. Elastase of Pseudomonas aeruginosa: inactivation of complement components and complement-derived chemotactic and phagocytic factors. Infect. Immun. 1974 10 : 128 35.
163. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science 2003 300 : 1524 5. (Pubitemid 36682871)
164. Ramphal R, Balloy V, Jyot J et al. Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin. J. Immunol. 2008 181 : 586 92.
165. John G, Yildirim AO, Rubin BK et al. TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells. Am. J. Respir. Cell Mol. Biol. 2010 42 : 424 31.
166. Bajmoczi M, Gadjeva M, Alper SL et al. Cystic fibrosis transmembrane conductance regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosa. Am. J. Physiol. Cell Physiol. 2009 297 : C263 77.
167. Reiniger N, Lee MM, Coleman FT et al. Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor. Infect. Immun. 2007 75 : 1598 608. (Pubitemid 46559423)
168. Lillehoj EP, Kim H, Chun EY et al. Pseudomonas aeruginosa stimulates phosphorylation of the airway epithelial membrane glycoprotein Muc1 and activates MAP kinase. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004 287 : L809 15. (Pubitemid 39249394)
169. Vollmer J. TLR9 in health and disease. Int. Rev. Immunol. 2006 25 : 155 81. (Pubitemid 44034579)
170. Hacker H, Vabulas RM, Takeuchi O et al. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J. Exp. Med. 2000 192 : 595 600. (Pubitemid 30666261)
171. Travassos LH, Carneiro LA, Girardin SE et al. Nod1 participates in the innate immune response to Pseudomonas aeruginosa. J. Biol. Chem. 2005 280 : 36714 18.
172. Travassos LH, Carneiro LA, Girardin S et al. Nod proteins link bacterial sensing and autophagy. Autophagy 2010 6 : 409 11.
173. Koh AY, Priebe GP, Ray C et al. Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia. Infect. Immun. 2009 77 : 5300 10.
174. Tsai WC, Strieter RM, Mehrad B et al. CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. Infect. Immun. 2000 68 : 4289 96. (Pubitemid 30434585)
175. Mizgerd JP, Horwitz BH, Quillen HC et al. Effects of CD18 deficiency on the emigration of murine neutrophils during pneumonia. J. Immunol. 1999 163 : 995 9.
176. Langrish CL, McKenzie BS, Wilson NJ et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 2004 202 : 96 105.
177. Fang FC. Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J. Clin. Invest. 1997 99 : 2818 25.
178. Dubin RF, Robinson SK, Widdicombe JH. Secretion of lactoferrin and lysozyme by cultures of human airway epithelium. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004 286 : L750 5.
179. Leid JG, Kerr M, Selgado C et al. Flagellum-mediated biofilm defense mechanisms of Pseudomonas aeruginosa against host-derived lactoferrin. Infect. Immun. 2009 77 : 4559 66.
180. Cole AM, Liao HI, Stuchlik O et al. Cationic polypeptides are required for antibacterial activity of human airway fluid. J. Immunol. 2002 169 : 6985 91. (Pubitemid 36899286)
181. Cole AM, Thapa DR, Gabayan V et al. Decreased clearance of Pseudomonas aeruginosa from airways of mice deficient in lysozyme M. J. Leukoc. Biol. 2005 78 : 1081 5. (Pubitemid 41572471)
182. Martinez JG, Waldon M, Huang Q et al. Membrane-targeted synergistic activity of docosahexaenoic acid and lysozyme against Pseudomonas aeruginosa. Biochem. J. 2009 419 : 193 200.
183. Kato A, Schleimer RP. Beyond inflammation: airway epithelial cells are at the interface of innate and adaptive immunity. Curr. Opin. Immunol. 2007 19 : 711 20. (Pubitemid 350236807)
184. Cheng DS, Han W, Chen SM et al. Airway epithelium controls lung inflammation and injury through the NF-kappa B pathway. J. Immunol. 2007 178 : 6504 13. (Pubitemid 46717434)
185. Chen SM, Cheng DS, Williams BJ et al. The nuclear factor kappa-B pathway in airway epithelium regulates neutrophil recruitment and host defence following Pseudomonas aeruginosa infection. Clin. Exp. Immunol. 2008 153 : 420 8.
186. Zhang Z, Louboutin JP, Weiner DJ et al. Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5. Infect. Immun. 2005 73 : 7151 60. (Pubitemid 41587612)
187. Kannan S, Huang H, Seeger D et al. Alveolar epithelial type II cells activate alveolar macrophages and mitigate P. aeruginosa infection. PLoS One 2009 4 : e4891.
188. Regamey N, Obregon C, Ferrari-Lacraz S et al. Airway epithelial IL-15 transforms monocytes into dendritic cells. Am. J. Respir. Cell Mol. Biol. 2007 37 : 75 84. (Pubitemid 46999539)
189. Sauty A, Dziejman M, Taha RA et al. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J. Immunol. 1999 162 : 3549 58. (Pubitemid 29313608)
190. Panina-Bordignon P, Papi A, Mariani M et al. The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J. Clin. Invest. 2001 107 : 1357 64. (Pubitemid 32522029)
191. Grassme H, Kirschnek S, Riethmueller J et al. CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science 2000 290 : 527 30.
192. Grassme H, Jendrossek V, Riehle A et al. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat. Med. 2003 9 : 322 30. (Pubitemid 36362788)
193. Hotchkiss RS, Dunne WM, Swanson PE et al. Role of apoptosis in Pseudomonas aeruginosa pneumonia. Science 2001 294 : 1783.
194. Speert DP, Wright SD, Silverstein SC et al. Functional characterization of macrophage receptors for in vitro phagocytosis of unopsonized Pseudomonas aeruginosa. J. Clin. Invest. 1988 82 : 872 9.
195. Cheung DO, Halsey K, Speert DP. Role of pulmonary alveolar macrophages in defense of the lung against Pseudomonas aeruginosa. Infect. Immun. 2000 68 : 4585 92. (Pubitemid 30497727)
196. Kooguchi K, Hashimoto S, Kobayashi A et al. Role of alveolar macrophages in initiation and regulation of inflammation in Pseudomonas aeruginosa pneumonia. Infect. Immun. 1998 66 : 3164 9. (Pubitemid 28303112)
197. Ojielo CI, Cooke K, Mancuso P et al. Defective phagocytosis and clearance of Pseudomonas aeruginosa in the lung following bone marrow transplantation. J. Immunol. 2003 171 : 4416 24. (Pubitemid 37238721)
198. Morissette C, Francoeur C, Darmond-Zwaig C et al. Lung phagocyte bactericidal function in strains of mice resistant and susceptible to Pseudomonas aeruginosa. Infect. Immun. 1996 64 : 4984 92. (Pubitemid 26403951)
199. Deriy LV, Gomez EA, Zhang G et al. Disease-causing mutations in the cystic fibrosis transmembrane conductance regulator determine the functional responses of alveolar macrophages. J. Biol. Chem. 2009 284 : 35926 38.
200. Meyer M, Huaux F, Gavilanes X et al. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 2009 41 : 590 602.
201. Wong CK, Cheung PF, Ip WK et al. Intracellular signaling mechanisms regulating toll-like receptor-mediated activation of eosinophils. Am. J. Respir. Cell Mol. Biol. 2007 37 : 85 96.
202. Linch SN, Kelly AM, Danielson ET et al. Mouse eosinophils possess potent antibacterial properties in vivo. Infect. Immun. 2009 77 : 4976 82.
203. Pene F, Zuber B, Courtine E et al. Dendritic cells modulate lung response to Pseudomonas aeruginosa in a murine model of sepsis-induced immune dysfunction. J. Immunol. 2008 181 : 8513 20.
204. Gosselin D, DeSanctis J, Boule M et al. Role of tumor necrosis factor alpha in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa. Infect. Immun. 1995 63 : 3272 8.
205. Lee JH, Del SL, Khine AA et al. Modulation of bacterial growth by tumor necrosis factor-alpha in vitro and in vivo. Am. J. Respir. Crit. Care Med. 2003 168 : 1462 70.
206. Choi S, Park YS, Koga T et al. TNF- is a key regulator of MUC1, an anti-inflammatory molecule during airway Pseudomonas aeruginosa infection. Am. J. Respir. Cell Mol. Biol. 2010 (in press).
207. Mayer-Hamblett N, Aitken ML, Accurso FJ et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2007 175 : 822 8. (Pubitemid 46631794)
208. Schultz MJ, Rijneveld AW, Florquin S et al. Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002 282 : L285 90. (Pubitemid 34654680)
209. Schultz MJ, Knapp S, Florquin S et al. Interleukin-18 impairs the pulmonary host response to Pseudomonas aeruginosa. Infect. Immun. 2003 71 : 1630 4. (Pubitemid 36368690)
210. McAllister F, Henry A, Kreindler JL et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J. Immunol. 2005 175 : 404 12. (Pubitemid 40884344)
211. Dubin PJ, McAllister F, Kolls JK. Is cystic fibrosis a TH17 disease? Inflamm. Res. 2007 56 : 221 7.
212. Dubin PJ, Kolls JK. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007 292 : L519 28.
213. Moser C, Kjaergaard S, Pressler T et al. The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS 2000 108 : 329 35. (Pubitemid 30456361)
214. Jain-Vora S, LeVine AM, Chroneos Z et al. Interleukin-4 enhances pulmonary clearance of Pseudomonas aeruginosa. Infect. Immun. 1998 66 : 4229 36. (Pubitemid 28402696)
215. Lei D, Lancaster JR Jr., Joshi MS et al. Activation of alveolar macrophages and lung host defenses using transfer of the interferon-gamma gene. Am. J. Physiol. 1997 272 : L852 9. (Pubitemid 27241932)
216. Schultz MJ, Rijneveld AW, Speelman P et al. Endogenous interferon-gamma impairs bacterial clearance from lungs during Pseudomonas aeruginosa pneumonia. Eur. Cytokine Netw. 2001 12 : 39 44. (Pubitemid 32281187)
217. El-Benna J, Dang PM, Gougerot-Pocidalo MA et al. p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases. Exp. Mol. Med. 2009 41 : 217 25.
218. phox deficiency impairs NF-kappa B activation and host defense in Pseudomonas pneumonia. J. Immunol. 2004 172 : 1801 8. (Pubitemid 38116828)
219. Webert KE, Vanderzwan J, Duggan M et al. Effects of inhaled nitric oxide in a rat model of Pseudomonas aeruginosa pneumonia. Crit. Care Med. 2000 28 : 2397 405. (Pubitemid 30604445)
220. Hopkins N, Gunning Y, O'Croinin DF et al. Anti-inflammatory effect of augmented nitric oxide production in chronic lung infection. J. Pathol. 2006 209 : 198 205. (Pubitemid 43805415)
221. Grasemann H, Schwiertz R, Matthiesen S et al. Increased arginase activity in cystic fibrosis airways. Am. J. Respir. Crit. Care Med. 2005 172 : 1523 8. (Pubitemid 43076540)
222. Winnie GB, Cowan RG. Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function. Pediatr. Pulmonol. 1991 10 : 92 100.
223. Moser C, Johansen HK, Song Z et al. Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice. APMIS 1997 105 : 838 42. (Pubitemid 27483630)
224. Ziegler SF. FOXP3: of mice and men. Annu. Rev. Immunol. 2006 24 : 209 26.
225. O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010 327 : 1098 102.
226. Carrigan SO, Yang YJ, Issekutz T et al. Depletion of natural CD4+CD25+ T regulatory cells with anti-CD25 antibody does not change the course of Pseudomonas aeruginosa-induced acute lung infection in mice. Immunobiology 2009 214 : 211 22.
227. Nieuwenhuis EE, Matsumoto T, Exley M et al. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat. Med. 2002 8 : 588 93. (Pubitemid 34633436)
228. Kinjo T, Nakamatsu M, Nakasone C et al. NKT cells play a limited role in the neutrophilic inflammatory responses and host defense to pulmonary infection with Pseudomonas aeruginosa. Microbes Infect 2006 8 : 2679 85. (Pubitemid 44767736)
229. Noda Y, Yasuoka S, Inoue I et al. Analysis of IgA antibody to Pseudomonas aeruginosa in sera and sputa of patients with chronic airway diseases. Intern. Med. 1992 31 : 575 82. (Pubitemid 20358490)
230. Chen SM, Sheu JN, Chen JP et al. Community-acquired Pseudomonas aeruginosa pneumonia complicated with loculated empyema in an infant with selective IgA deficiency. Acta Paediatr. Taiwan. 2002 43 : 157 61.
231. Amin PB, Diebel LN, Liberati DM. Secretory immunoglobulin A abrogates inflammatory responses and improves mortality after Pseudomonas pneumonia. J. Trauma 2010 68 : 827 33.
232. Doring G, Meisner C, Stern M. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl. Acad. Sci. U.S.A. 2007 104 : 11020 5. (Pubitemid 47175219)
233. Doring G, Pfeiffer C, Weber U et al. Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals. Am. J. Respir. Crit. Care Med. 1995 151 : 983 5.